Outset Medical, Inc. to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 11, 2026

Outset Medical will announce Q4 2025 financial results on February 11, 2026, followed by a conference call with executives.

Quiver AI Summary

Outset Medical, Inc., a medical technology company focused on improving dialysis, announced that it will release its financial results for the fourth quarter and full year of 2025 on February 11, 2026, after the market closes. The company will hold a conference call at 1:30 p.m. Pacific time to discuss these results, led by CEO Leslie Trigg and CFO Renee Gaeta. Participants can register online to obtain dial-in numbers for the call. Outset Medical is known for its innovative Tablo® Hemodialysis System, which integrates water purification and on-demand dialysate production, enhancing dialysis care in over 1,000 U.S. healthcare facilities. The company's technology aims to simplify the dialysis process and improve patient and provider experiences in kidney care. More information is available on their website.

Potential Positives

Outset Medical is set to release its financial results for Q4 and full-year 2025, indicating transparency and proactive communication with stakeholders.
The conference call allows for direct engagement with executives, fostering investor relations and building trust.
The Tablo® Hemodialysis System is FDA-cleared and trusted by over 1,000 healthcare facilities, highlighting the company's established presence and credibility in the dialysis market.
Outset's innovative approach to kidney care has the potential to improve operational, clinical, and financial outcomes for healthcare providers, indicating a strong value proposition.

Potential Negatives

The press release does not provide any details about the financial results expected for the fourth quarter and full-year 2025, which may raise concerns among investors about the company's financial performance.
There is no mention of any new product developments or advancements in technology, which could indicate a lack of innovation or growth potential in a competitive market.
The disclosure about the upcoming conference call does not include any specific expectations or guidance, possibly reflecting uncertainty or caution from management regarding the company's future outlook.

FAQ

What are the financial results release dates for Outset Medical?

Outset Medical will release its financial results for Q4 and full-year 2025 on February 11, 2026.

Who will host the conference call for Outset Medical's financial results?

The conference call will be hosted by Leslie Trigg, CEO, and Renee Gaeta, CFO.

What time will the conference call on February 11, 2026, begin?

The conference call will start at 1:30 p.m. Pacific time (4:30 p.m. Eastern time).

How can I join the Outset Medical conference call?

Participants can register online to receive dial-in numbers and a unique pin for the call.

Where can I find more information about Outset Medical?

More information is available on Outset Medical's website at www.outsetmedical.com.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$OM Insider Trading Activity

$OM insiders have traded $OM stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.

Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:

LESLIE TRIGG (Chair and CEO) has made 0 purchases and 5 sales selling 17,529 shares for an estimated $94,613.
JOHN L. BROTTEM (General Counsel) has made 0 purchases and 5 sales selling 11,489 shares for an estimated $61,273.
MARC NASH (EVP Operations R&D & Service) has made 0 purchases and 5 sales selling 6,953 shares for an estimated $37,127.
KAREN DREXLER sold 1,548 shares for an estimated $6,764

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$OM Revenue

$OM had revenues of $29.4M in Q3 2025. This is an increase of 2.67% from the same period in the prior year.

You can track OM financials on Quiver Quantitative's OM stock page.

$OM Hedge Fund Activity

We have seen 50 institutional investors add shares of $OM stock to their portfolio, and 45 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,621,137 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $22,890,454
DURABLE CAPITAL PARTNERS LP removed 633,420 shares (-38.2%) from their portfolio in Q3 2025, for an estimated $8,943,890
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 631,663 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $2,343,469
PURA VIDA INVESTMENTS, LLC removed 424,120 shares (-98.8%) from their portfolio in Q3 2025, for an estimated $5,988,574
MORGAN STANLEY added 311,805 shares (+256.9%) to their portfolio in Q3 2025, for an estimated $4,402,686
BLACKROCK, INC. added 265,065 shares (+26.9%) to their portfolio in Q3 2025, for an estimated $3,742,717
MILLENNIUM MANAGEMENT LLC added 262,874 shares (+165.8%) to their portfolio in Q3 2025, for an estimated $3,711,780

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$OM Analyst Ratings

Wall Street analysts have issued reports on $OM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 12/16/2025

To track analyst ratings and price targets for $OM, check out Quiver Quantitative's $OM forecast page.

$OM Price Targets

Multiple analysts have issued price targets for $OM recently. We have seen 3 analysts offer price targets for $OM in the last 6 months, with a median target of $17.0.

Here are some recent targets:

Rick Wise from Stifel set a target price of $8.0 on 01/07/2026
Marie Thibault from BTIG set a target price of $17.0 on 12/16/2025
Shagun Singh from RBC Capital set a target price of $17.0 on 11/11/2025

Full Release

SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026.

On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results.

Conference Call Details
The conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Wednesday, February 11, 2026. Those interested in joining the conference call may do so by registering online . Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .

About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com .

Contact
Jim Mazzola
[email protected]